Porcilis PCV
adjuvanted inactivated vaccine against porcine circovirus
Table of contents
Overview
This is a summary of the European public assessment report (EPAR). Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.
This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).
Authorisation details
Product details | |
---|---|
Name |
Porcilis PCV
|
Agency product number |
EMEA/V/C/000135
|
Active substance |
porcine circovirus type 2 ORF2 subunit antigen
|
International non-proprietary name (INN) or common name |
adjuvanted inactivated vaccine against porcine circovirus
|
Species |
Pigs
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI09AA07
|
Publication details | |
---|---|
Marketing-authorisation holder |
Intervet International BV
|
Revision |
7
|
Date of issue of marketing authorisation valid throughout the European Union |
12/01/2009
|
Contact address |
Wim de Körverstraat 35
5831 AN Boxmeer The Netherlands |
Product information
15/07/2021 Porcilis PCV - EMEA/V/C/000135 - II/0014/G
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Immunologicals for suidae
Therapeutic indication
For the active immunisation of pigs to reduce the virus load in blood and lymphoid tissues and to reduce weight loss associated with porcine-circovirus-type-2 infection occurring during the fattening period.
Onset of immunity: 2 weeks
Duration of immunity: 22 weeks